Search

Displaying results 6901 - 6910 of 10000 in total
  1. Drug

    Arsthinol

    go.drugbank.com/drugs/DB08928
    Experimental

    Arsthinol (INN) is an antiprotozoal agent that was first synthesized by Ernst A.H. Friedheim in 1949 via the complexing of acetarsol with 2,3-dimercaptopropanol. … Considered well tolerated when compared to other related trivalent organoarsenicals, arsthinol has even undergone recent studies as a potential anticancer agent.

  2. Drug

    Bifeprunox

    go.drugbank.com/drugs/DB04888
    Investigational

    Bifeprunox is a novel atypical antipsychotic agent which, along with SLV313, aripiprazole and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.

  3. Drug

    Butyrylcholinesterase

    go.drugbank.com/drugs/DB06352
    Investigational

  4. Drug

    Abexinostat

    go.drugbank.com/drugs/DB12565
    Investigational

    Abexinostat has been used in trials studying the treatment of Sarcoma, Lymphoma, Leukemia, Lymphocytic, and Hodgkin Disease, among others.

  5. Drug

    IN01

    go.drugbank.com/drugs/DB16434
    Experimental

    Of note, the IN01 vaccine is being tested in a Phase I clinical trial in patients with fibrosing interstitial lung disease resulting from SARS-CoV-2 infection (NCT04537130). … The study will explore the effect of this vaccine on pulmonary function, oxygen saturation, quality of life, and fibrosing status in addition to biomarkers and molecular markers of the vaccine.

  6. Drug

    Pegvisomant

    go.drugbank.com/drugs/DB00082
    ApprovedInvestigational

    Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediat...

  7. Drug

    Avasopasem manganese

    go.drugbank.com/drugs/DB16354
    Investigational

    [L27246, L27256] This drug has potential application for radiation-induced esophagitis and oral mucositis, in addition to being currently tested against COVID-19.

  8. Drug

    Neisseria meningitidis group A capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB15680
    ApprovedInvestigational

  9. Drug

    Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB15681
    ApprovedInvestigational

    Products: NeisVac-C Injektionssuspension in einer Fertigspritze
  10. Drug

    AP5346

    go.drugbank.com/drugs/DB04992
    Investigational

    AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer. It is being pursued by Access Pharmaceuticals, Inc.